Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05697198 · ClinicalTrials.gov registry record
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
A clinical trial of Breast Cancer and Lung Cancer, sponsored by Labcorp Corporation of America Holdings.
- Completed
- Registry status
- 1,429
- Enrollment target
- 8
- Study locations
NCT05697198 is a study of Breast Cancer and Lung Cancer that has completed, run by Labcorp Corporation of America Holdings. The registered enrollment target is 1,429 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (49% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05697198, a study of Breast Cancer and Lung Cancer, has completed, sponsored by Labcorp Corporation of America Holdings.
- COMPLETED
- Registry status
- 1,429 participants
- Enrollment target
- 8
- Study locations
Study Summary
The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next generation sequencing of time-matched or archival tissue specimens from individuals with advanced solid tumors. Examples of locally advanced and metastatic tumors include stage III and IV cancers (ex. lung, breast, all gastrointestinal malignancies, all gynecologic malignancies, prostate cancer, head and neck tumors, soft tissue cancers, and melanoma). These specimens will be analyzed for diagnostic purposes and research (either by Labcorp/OmniSeq or to a third-party recipient designated by Labcorp/OmniSeq). Labcorp/OmniSeq may transfer the specimens and data to its clients, including commercial, academic or non-profit research institutions; or alternatively, may retain the specimens in its repository for future research use at the sole discretion of Labcorp/OmniSeq and or assignees. Labcorp/OmniSeq will maintain all detailed clinical information including demographic data (de-identified), ethnicity, disease state, stage (radiological, pathological and clinical-whichever is relevant).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST OmniSeq Test
Study Locations (8)
Florida
- Clinical Site - Orange City
- Clinical Site - Stuart
Alabama
- Clinical Site - Fort Payne
Georgia
- Clinical Site - Dublin
Indiana
- Clinical Site - Fort Wayne
Louisiana
- Clinical Site - Covington
North Carolina
- Clinical Site - Huntersville
South Carolina
- Clinical Site - Rock Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,429 participants |
| Start Date | 2021-04-19 |
| Est. Completion | 2024-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05697198
The ClinicalTrials.gov registry entry for NCT05697198 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,429 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (49% lower). The listed sponsor is Labcorp Corporation of America Holdings, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which OmniSeq Test is the first listed.
NCT05697198 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Florida, Alabama, Georgia.
Frequently Asked Questions
What is clinical trial NCT05697198 about?
NCT05697198 is a clinical study titled "PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine". The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next generation sequencing of time-matched or archival tissue specimens from...
What is the current status of trial NCT05697198?
This trial is currently completed. The enrollment target is 1,429 participants. The study started on 2021-04-19. Estimated completion is 2024-12-31.
What conditions does trial NCT05697198 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT05697198?
The interventions under investigation include: OmniSeq Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05697198?
This trial is sponsored by Labcorp Corporation of America Holdings, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05697198 being conducted?
This trial has 8 study locations across Alabama, Florida, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.